Press Releases

Press Releases

  • April 22, 2020
    Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020
  • March 30, 2020
    Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
  • December 18, 2019
    Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer
  • November 7, 2019
    Aileron Therapeutics Reports Third Quarter 2019 Results
  • October 31, 2019
    Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th
  • October 29, 2019
    Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference
  • October 21, 2019
    Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th
  • October 16, 2019
    Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
  • September 28, 2019
    Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology
  • September 24, 2019
    Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology